As of March 31, 2025, Revelation had $3.7M in cash and cash equivalents, compared to $6.5M as of December 31, 2024. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through June 2025. “While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe burns,” said James Rolke, Chief Executive Officer of Revelation. “We are also looking forward to the Phase 1b PRIME clinical study topline data this summer.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue